Editorial
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Apr 7, 2009; 15(13): 1548-1553
Published online Apr 7, 2009. doi: 10.3748/wjg.15.1548
Table 2 Characteristics of papers included in the meta-analysis
StudyMean ageSex
IBS subtypeType of TCADaily dosageDuration of treatment/follow up (wk)
FemaleMale
Vahedi et al[16], 2008362129D-IBSAmitriptyline10 mg8
Talley et al[17], 2008ND2113D-IBS, C-IBS, Alt-IBSImipramine2 wk: 25 mg; Thereafter to the end: 50 mg12
Morgan et al[18], 200539220D-IBS, C-IBS, Alt-IBSAmitriptylineFirst week: 25 mg; Thereafter to the end: 50 mg4
Rajagopalan et al[19], 199834.81111NDAmitriptylineFirst week: 25 mg; 2nd week: 50 mg; Thereafter to the end: 75 mg12
Vij et al[20], 199132.51436D-IBS, C-IBS, Alt-IBSDoxepin75 mg6
Greenbaum et al[21], 198745.21811D-IBS, C-IBSDesipramineFirst week: 50 mg; 2nd week: 100 mg; Thereafter to the end: 150 mg6
Tripathi et al[22], 198337NDNDNDTrimipramine30 mg5